116 related articles for article (PubMed ID: 37989009)
1. Factors associated with advanced-stage diagnosis of cervical cancer in Estonia: a population-based study.
Šavrova A; Jaal J; Nõmm O; Innos K
Public Health; 2023 Dec; 225():369-375. PubMed ID: 37989009
[TBL] [Abstract][Full Text] [Related]
2. Effect of Pap-smear and sociodemographic factors on cervical cancer risk in Estonia: A population-based case-control study.
Nõmm O; Veerus P; Orumaa M; Innos K
Cancer Epidemiol; 2022 Oct; 80():102231. PubMed ID: 35901623
[TBL] [Abstract][Full Text] [Related]
3. Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014.
Ojamaa K; Innos K; Baburin A; Everaus H; Veerus P
BMC Cancer; 2018 Nov; 18(1):1075. PubMed ID: 30404606
[TBL] [Abstract][Full Text] [Related]
4. The impact of sociodemographic factors on the utilization of radiation therapy in breast cancer patients in Estonia: a register-based study.
Shahrabi Farahani F; Paapsi K; Innos K
Int J Equity Health; 2021 Jun; 20(1):152. PubMed ID: 34193144
[TBL] [Abstract][Full Text] [Related]
5. Age-specific and genotype-specific carcinogenic human papillomavirus prevalence in a country with a high cervical cancer burden: results of a cross-sectional study in Estonia.
Pärna K; Nygård M; Tisler A; Toompere K; Naaber P; Ratnik K; Ķīvīte Urtāne A; Zodzika J; Stankūnas M; Baltzer N; Uusküla A
BMJ Open; 2023 Jun; 13(6):e069558. PubMed ID: 37263686
[TBL] [Abstract][Full Text] [Related]
6. Divergent trends in lung cancer incidence by gender, age and histological type in Estonia: a nationwide population-based study.
Aareleid T; Zimmermann ML; Baburin A; Innos K
BMC Cancer; 2017 Aug; 17(1):596. PubMed ID: 28854969
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer screening patterns among HIV-positive women in Estonia: a population-based retrospective cohort study.
Tisler A; Ojavee SE; Veerus P; Soodla P; Uusküla A
BMC Cancer; 2021 Apr; 21(1):350. PubMed ID: 33794821
[TBL] [Abstract][Full Text] [Related]
8. Prospects for phase III-IV HPV vaccination trials in the Nordic countries and in Estonia.
Lehtinen M; Kibur M; Luostarinen T; Anttila A; Pukkala E
J Clin Virol; 2000 Oct; 19(1-2):113-22. PubMed ID: 11091154
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs. an unscreened population.
Aareleid T; Pukkala E; Thomson H; Hakama M
Eur J Cancer; 1993; 29A(5):745-9. PubMed ID: 8471334
[TBL] [Abstract][Full Text] [Related]
10. Inequalities in reported use of cervical screening in Estonia: results from cross-sectional studies in 2004-2020.
Suurna M; Orumaa M; Ringmets I; Pärna K
BMC Womens Health; 2022 Dec; 22(1):545. PubMed ID: 36566176
[TBL] [Abstract][Full Text] [Related]
11. Prevaccination Prevalence of Type-Specific Human Papillomavirus Infection by Grade of Cervical Cytology in Estonia.
Uusküla A; Oja M; Tamm S; Tisler A; Laanpere M; Padrik L; Nygard M; Reisberg S; Vilo J; Kolde R
JAMA Netw Open; 2023 Feb; 6(2):e2254075. PubMed ID: 36745455
[TBL] [Abstract][Full Text] [Related]
12. A Qualitative Study of Parental Knowledge and Perceptions of Human Papillomavirus and Cervical Cancer Prevention in Rural Central Java, Indonesia: Understanding Community Readiness for Prevention Interventions.
Spagnoletti BRM; Bennett LR; Wahdi AE; Wilopo SA; Keenan CA
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2429-2434. PubMed ID: 31450917
[TBL] [Abstract][Full Text] [Related]
13. Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study.
Padrik P; Valter A; Valter E; Baburin A; Innos K
Acta Oncol; 2017 Jan; 56(1):52-58. PubMed ID: 27796149
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus self-sampling for long-term non-attenders in cervical cancer screening: A randomised feasibility study in Estonia.
Veerus P; Hallik R; Jänes J; Jõers K; Paapsi K; Laidra K; Innos K
J Med Screen; 2022 Mar; 29(1):53-60. PubMed ID: 34694179
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
16. Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia.
Veerus P; Arbyn M; Amati C; Paolo B;
Tumori; 2010; 96(4):524-8. PubMed ID: 20968130
[TBL] [Abstract][Full Text] [Related]
17. Time trends in population-based breast cancer survival in Estonia: analysis by age and stage.
Baburin A; Aareleid T; Padrik P; Valvere V; Innos K
Acta Oncol; 2014 Feb; 53(2):226-34. PubMed ID: 23767956
[TBL] [Abstract][Full Text] [Related]
18. The epidemiological and economic impact of a quadrivalent human papillomavirus (hpv) vaccine in Estonia.
Uusküla A; Müürsepp A; Kawai K; Raag M; Jürisson M; Pillsbury M
BMC Infect Dis; 2013 Jul; 13():304. PubMed ID: 23819789
[TBL] [Abstract][Full Text] [Related]
19. Increasing kidney cancer incidence and survival in Estonia: role of age and stage.
Innos K; Sepp T; Baburin A; Kotsar A; Lang K; Padrik P; Aareleid T
Acta Oncol; 2019 Jan; 58(1):21-28. PubMed ID: 30280624
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
